
## Additions and Corrections

## 2005, Volume 48

Sarah Ulmschneider, Ursula Müller-Vieira, Christian D. Klein, Iris Antes, Thomas Lengauer, Rolf W. Hartmann\*: Synthesis and Evaluation of (Pyridylmethylene)tetrahydronaphthalenes/-indanes and Structurally Modified Derivatives: Potent and Selective Inhibitors of Aldosterone Synthase

Pages 1567 and 1568. In Tables 2 and 3, the column of values for the % inhibition for human CYP17 and the columns of values for IC<sub>50</sub> for V79 11B1 hCP11B1 and V79 11B2 hCYP11B2 were swapped with one another. The correct versions of both tables are shown below.

Table 2. 4-Pyridylmethylenetetrahydronaphthalenes and -indanes: Inhibition of Human Adrenal CYP11B1 and CYP11B2, Human CYP17, and Human CYP19 in Vitro



2a/b, 6a/b, 8a/b, 10a/b, 12a/b, 16a/b, 22a/b

4a, 14a/b, 18a

			% inhibition		IC <sub>50</sub> (nM)			
compd	X	isomer	human hCYP11B2 <sup>a,b</sup>	human CYP17 <sup>c,d</sup>	V79 11B1 hCYP11B1 <sup>e,f</sup>	V79 11B2 hCYP11B2 <sup>e,g</sup>	human CYP19 <sup>h,i</sup>	$\begin{array}{c} \text{selectivity} \\ \text{factor}^{j} \end{array}$
2a	Н	E	55	8	nd	nd	6700	
<b>2b</b>	H	Z	nd	18	1315	931	12730	1.4
4a	H	E	54	15	282	143	650	2.0
6a	5-F	E	37	15	380	1098	1550	0.3
<b>6b</b>	5-F	$\boldsymbol{Z}$	77	29	257	34	800	7.6
8a	5-Cl	E	38	18	243	1515	5430	0.2
8b	5-Cl	Z	37	36	1122	301	1990	3.7
10a	5-Br	E	17	24	948	2640	>36000	0.4
10b	5-Br	$\boldsymbol{Z}$	40	56	877	484	3400	1.8
12a	5-OMe	$\boldsymbol{E}$	11	59	nd	nd	3960	
12b	5-OMe	$\boldsymbol{Z}$	13	55	nd	nd	3720	
14a	6-OMe	E	31	22	nd	nd	800	
14b	6-OMe	$\boldsymbol{Z}$	36	56	nd	nd	1010	
16a	6-OMe	$egin{array}{c} E \ Z \end{array}$	26	3	nd	nd	280	
16b	6-OMe	$\boldsymbol{Z}$	24	26	nd	nd	770	
18a	6,7-di-OMe	$\boldsymbol{E}$	29	11	nd	nd	90	
22a	$6 ext{-Me}$	$\boldsymbol{E}$	41	4	nd	nd	1280	
22b	$6 ext{-Me}$	$\boldsymbol{Z}$	46	8	nd	nd	1710	
ketoconazole			36	40	224	81	nd	2.8
fadrozole			68	5	10	1	30	10

 $<sup>^</sup>a$  Mean value of four determinations, standard deviation less than 10%.  $^b$  S. pombe expressing human CYP11B2; substrate deoxycorticosterone, 100 nM; inhibitor, 500 nM.  $^c$  Mean value of four determinations, standard deviation less than 10%.  $^d$  E. coli expressing human CYP17; 5 mg/mL of protein; substrate progesterone, 2.5  $\mu$ M; inhibitor, 2.5  $\mu$ M.  $^e$  Mean value of four determinations, standard deviation less than 20%. nd = not determined.  $^f$  Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 100 nM.  $^g$  Hamster fibroblasts expressing human CYP11B2; substrate deoxycorticosterone, 100 nM.  $^h$  Mean value of four determinations, standard deviation less than 5%. nd = not determined.  $^i$  Human placental CYP19; 1 mg/mL of protein; substrate androstenedione, 500 nM.  $^j$  IC50 CYP11B1/IC50 CYP11B2.

Table 3. Structural Modifications of the Title Compounds: Inhibition of Human Adrenal CYP11B1 and CYP11B2, Human CYP17, and Human CYP19 in Vitro

		% inhibition					
$\operatorname{compd}$	isomer	human hCYP11B2 <sup>a,b</sup>	human CYP17 <sup>c,d</sup>	V79 11B1 hCYP11B1 <sup>e,f</sup>	V79 11B2 hCYP11B2 <sup>e,g</sup>	$\overline{\text{human}}_{\text{CYP19}^{h,i}}$	$\begin{array}{c} \text{selectivity} \\ \text{factor}^j \end{array}$
27a	E	18	17	nd	nd	4330	
27b	Z	17	5	nd	nd	4830	
28a	E	72	6	3179	27	7450	118
28b	Z	14	0	nd	nd	790	
29a	$egin{array}{c} E \ Z \end{array}$	0	14	nd	nd	>36000	
29b	Z	0	31	nd	nd	>36000	
30a	$\boldsymbol{E}$	60	57	1129	58	720	19.5
30b	$egin{array}{c} E \ Z \ E \ Z \end{array}$	91	65	374	26	1940	14.4
31a	E	0	20	nd	nd	>36000	
31b	Z	0	14	nd	nd	>36000	
32		0	6	nd	nd	4810	
33		5	9	nd	nd	3630	
34		6	5	nd	nd	2740	
35		32	22	nd	nd	100	
36a	E	47	13	nd	nd	3680	
36b	$egin{array}{c} Z \ E \ E \end{array}$	15	41	nd	nd	2800	
37a	E	0	3	nd	nd	4060	
38a	E	67	nd	159	96	nd	1.7
ketoconazole		36	40	224	81	nd	2.8
fadrozole		68	5	10	1	30	10

 $^a$  Mean value of four determinations, standard deviation less than 10%.  $^b$  S. pombe expressing human CYP11B2; substrate deoxycorticosterone, 100 nM; inhibitor, 500 nM.  $^c$  Mean value of four determinations, standard deviation less than 10%.  $^d$  E. coli expressing human CYP17; 5 mg/mL of protein; substrate progesterone, 2.5  $\mu$ M; inhibitor, 2.5  $\mu$ M.  $^e$  Mean value of four determinations, standard deviation less than 20%. nd = not determined.  $^f$  Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 100 nM.  $^g$  Hamster fibroblasts expressing human CYP11B2; substrate deoxycorticosterone, 100 nM.  $^h$  Mean value of four determinations, standard deviation less than 5%. nd = not determined.  $^i$  Human placental CYP19; 1 mg/mL of protein; substrate androstenedione, 500 nM.  $^j$  IC50 CYP11B1/IC50 CYP11B2.

JM058022P

10.1021/jm058022p

Published on Web 05/19/2005